Role of structural MRI in Alzheimers disease 英文参考文献.docVIP

Vemuri and Jack Jr Alzheimer’s Research Therapy 2010,2:23 /content/2/4/23 RE VIE W Role of structural MRI in Alzheimer’s disease Prashanthi Vemuri* and Cli? ord R Jack Jr biomarker data and is adapted and illustrated in Figure 1. Abstract Owing to the close relationship between neuro degenera- tion and cognition (as illustrated in Figure 1), atrophy measured on structural magnetic resonance imaging (sMRI) is a powerful AD biomarker. Atrophy measured on structural magnetic resonance imaging (sMRI) is a powerful biomarker of the stage and intensity of the neurodegenerative aspect of Alzheimer’s disease (AD) pathology. In this review, we will discuss the role of sMRI as an AD biomarker by summarizing (a) the most commonly used methods to extract information from sMRI images, (b) the di?erent roles in which sMRI can be used as an AD biomarker, and (c) comparisons of sMRI with other major AD biomarkers. sMRI measures brain morphometry and therefore can capture gray matter atrophy related to the loss of neurons, synapses, and dendritic de-arborization that occurs on a microscopic level in AD; white matter atrophy related to the loss of structural integrity of white matter tracts, presumably resulting from demyelination and dying back of axonal processes; and ex vacuo expansion of cerebrospinal ? uid (CSF) spaces. Since there is a signi? cant negative correlation between NFT density and neuronal counts [10], sMRI indirectly re? ects NFT density. It has been shown that neuronal loss correlates Pathological cascade and structural magnetic resonance imaging Alzheimer’s disease (AD) is a multifaceted disease in with but exceeds NFT density in AD and is related which cumulative pathological brain insults result in directly to impaired cognitive function [10]. Neuronal progressive cognitive decline that ultimately leads to loss al